Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

A technology of beclomethasone dipropionate and formoterol, applied in the field of prevention and/or treatment of exacerbation of asthma, intermittent asthma and/or acute exacerbation of chronic asthma, which can solve the problems of poor patient compliance, inadequate treatment, quality of life Effects and other issues, achieve the effect of reducing bronchoconstriction and improving usability

Active Publication Date: 2010-02-24
CHIESI FARM SPA
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Treatment with different drugs and devices can lead to poor patient compliance with treatment, with possible consequences of inadequate treatment and negative impact on their quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] The pressurized metered-dose inhaler solution formulation of the combination formoterol fumarate + beclomethasone dipropionate contains formoterol fumarate dihydrate 6 μg / dose (0.010% w / w, based on the total weight), beclomethasone dipropionate 100 μg / dose (0.172% w / w), ethanol 12% w / w (as a co-solvent) and hydrochloric acid (1M) 0.024% w / w (as a stabilizer), and used as The HFA 134a of the propellant is made up to 100%. The formulations were packaged in aluminum cans equipped with 50 microliter valves.

Embodiment 2

[0054] The pressurized metered-dose inhaler solution formulation of the combination formoterol fumarate + beclomethasone dipropionate contains formoterol fumarate dihydrate 6 μg / dose (0.008% w / w, based on the total volume of the formulation). weight), beclomethasone dipropionate 200 μg / dose (0.271% w / w), ethanol 12% w / w (as co-solvent) and hydrochloric acid (1M) 0.019% w / w (as stabilizer) and used as propellant The HFA 134a of the agent was supplemented to 100%. The formulations were packaged in aluminum cans fitted with 63 microliter valves.

Embodiment 3

[0056] The dry powder inhaler formulation of the combination formoterol fumarate + beclomethasone dipropionate contains micronized formoterol fumarate dihydrate 6 μg / dose (0.06% w / w, based on the total weight of the formulation ), micronized beclomethasone dipropionate 100 μg / dose (1% w / w), 989 μg / dose premixed mixture (9.89% w / w) (composed of 98:2 w / w micronized lactose and magnesium stearate), 8904 μg / dose of coarse alpha-lactose monohydrate (89.04% w / w) with a particle size of 212-355 μm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of a composition comprising a fixed combination of a) formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclometasone dipropionate; for the manufacture of a medicament for use in the prevention and / or treatment of an exacerbation of asthma, intermittent asthma and / or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief, when needed.

Description

field of invention [0001] The present invention relates to a composition comprising a fixed combination of formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclomethasone dipropionate for the manufacture of a medicament Use, the medicament is for preventing and / or treating exacerbation of asthma, intermittent asthma and / or acute exacerbation of chronic asthma during the maintenance treatment of asthma with the same composition, for reducing symptoms when needed. [0002] The present invention additionally relates to the prevention and / or treatment of exacerbations, intermittent A method for asthma and / or exacerbations of chronic asthma to relieve symptoms when needed. Background of the invention [0003] Asthma is a disease that is becoming more prevalent and is the most common childhood illness. It can be identified by recurrent stridor and intermittent airflow limitation. Despite many advances in understanding it, ast...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/167A61K31/57A61P11/06
CPCA61K31/167A61K31/57A61P11/00A61P11/06A61P43/00A61K2300/00A61K9/0075A61K9/008A61K9/1623
Inventor P·奇斯I·龙德里D·埃瑟比G·波利
Owner CHIESI FARM SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap